<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511326</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.114384</org_study_id>
    <nct_id>NCT03511326</nct_id>
  </id_info>
  <brief_title>PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK</brief_title>
  <acronym>SESAME 2</acronym>
  <official_title>Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional open label prospective and multicentre study conducted in Germany in subjects&#xD;
      with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the&#xD;
      face (e.g., forehead or cheek or chin), excluding nose eyelids, lips and mucosa or balding&#xD;
      scalp, using Luxerm® DL-PDT treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Subject Satisfaction the Day of Treatment After Daylight Session</measure>
    <time_frame>the day of treatment after daylight session</time_frame>
    <description>Percentage of subjects satisfied and very satisfied globally with Luxerm Daylight procedure, the day of treatment after daylight session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Subject Satisfaction at Week 12 Post-treatment</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects satisfied or very satisfied (overall) with Luxerm DL procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Luxerm®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl Aminolaevulinate 16% Cream</intervention_name>
    <description>Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy</description>
    <arm_group_label>Luxerm®</arm_group_label>
    <other_name>160mg/g of methyl aminolevulinate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age &gt; 18 years old.&#xD;
&#xD;
          2. Subject with at least 5 clinically confirmed thin or non-hyperkeratotic and&#xD;
             non-pigmented actinic keratoses in an anatomical area on the face (e.g., forehead or&#xD;
             cheek or chin) excluding nose, eyelids, lips and mucosa, or balding scalp, at baseline&#xD;
             visit.&#xD;
&#xD;
          3. Subject or caregiver capable of performing the skin preparation and Luxerm® treatment&#xD;
             application as per the investigator instructions.&#xD;
&#xD;
          4. Female subject of childbearing potential must have a negative UPT at baseline (UPT&#xD;
             should have a sensitivity of 25 IU/L or less) and agree to be strictly abstinent or&#xD;
             use a highly effective method of birth control during the study (i.e. progestogen-only&#xD;
             oral hormonal contraception; male or female condom; cap, diaphragm or sponge with&#xD;
             spermicide; bilateral tubal ligation; combined (estrogen and progestogen-containing)&#xD;
             oral hormonal contraception, or injectable or implants hormonal contraception (at a&#xD;
             stable dose for at least 1 month prior to baseline); intra-uterine devices inserted at&#xD;
             least 1 month prior to baseline; vasectomized partner for at least 3 months prior to&#xD;
             baseline).&#xD;
&#xD;
          5. Female subject of non-childbearing potential, e.g.: post-menopausal (absence of&#xD;
             menstrual bleeding for 1 year without any other medical reason), hysterectomy or&#xD;
             bilateral ovariectomy.&#xD;
&#xD;
          6. Subject has read and signed the approved informed consent form (ICF) prior to any&#xD;
             participation in the study.&#xD;
&#xD;
          7. Subject has read and signed a Photograph Release Consent Form if he/she is willing to&#xD;
             be photographed.&#xD;
&#xD;
          8. Subject (or caregiver) willing and able to comply with all of the time commitments and&#xD;
             procedural requirements of the clinical trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with a clinical diagnosis of a skin disease other than AK (including&#xD;
             non-melanoma skin cancer) on the target anatomical area.&#xD;
&#xD;
          2. Subject with severe AK (thick, hyperkeratotic AK) per anatomical area (face or scalp).&#xD;
&#xD;
          3. Subject with clinical diagnosis of other skin disease on the target anatomical area.&#xD;
&#xD;
          4. Subject with pigmented AK on the target anatomical area.&#xD;
&#xD;
          5. Subject with melanoma at any location.&#xD;
&#xD;
          6. Immunocompromised subject or requiring immunosuppressive therapies.&#xD;
&#xD;
          7. Subject with porphyria; photosensitivity- related disorders, active infectious&#xD;
             disease.&#xD;
&#xD;
          8. Subject with known or suspected hypersensitivity to the active substance or to any&#xD;
             excipients of Luxerm® (see Summary of Product Characteristics).&#xD;
&#xD;
          9. Female subject who is pregnant, nursing or planning a pregnancy during the study.&#xD;
&#xD;
         10. Subject who has used any of the following topical preparations on the area to be&#xD;
             treated: keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.&#xD;
             glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%)&#xD;
             within 2 days of initiation of treatment.&#xD;
&#xD;
         11. Subject with a wash-out period from baseline for topical or systemic treatment or&#xD;
             medical/surgical procedure in the anatomical area (for AKs) less than the following:&#xD;
&#xD;
               -  Retinoids, including tazarotene, adapalene, tretinoin, retinol ==&gt; 4 weeks&#xD;
&#xD;
               -  Cryotherapy, diclofenac, corticosteroids or other treatments for AK==&gt; 8 weeks&#xD;
&#xD;
               -  Microdermabrasion, laser ablative treatments or chemical peels ==&gt;8 weeks&#xD;
&#xD;
               -  5-FU, imiquimod ==&gt;24 weeks&#xD;
&#xD;
               -  Surgical: excision and reconstructive surgery, chemosurgery, ==&gt;12 weeks&#xD;
&#xD;
               -  Any Photodynamic Therapy, ingenol mebutate (Pep-005), Radiotherapy and UV&#xD;
                  radiation therapy==&gt;12 weeks&#xD;
&#xD;
               -  Investigational therapies for Actinic Keratoses==&gt;12 weeks&#xD;
&#xD;
               -  Immunosuppressive drugs (such as glucocorticoids, cytostatic, antibodies, drugs&#xD;
                  acting on interferon, opioids, TNF binding proteins, Mycophenolate, small&#xD;
                  biologics agents)==&gt;12 weeks&#xD;
&#xD;
         12. Subject who is currently participating to/ or who has participated in another&#xD;
             investigational treatment or device research study within 4 weeks of baseline visit.&#xD;
&#xD;
         13. Subject may be unreliable for the study including subjects who engage in excessive&#xD;
             alcohol intake or drug abuse, or subjects who are unable to return for scheduled&#xD;
             follow-up visits.&#xD;
&#xD;
         14. Subject who is unable to communicate or cooperate with the investigator due to&#xD;
             language problems, poor mental development, or impaired cerebral function.&#xD;
&#xD;
         15. Subject who is unwilling to refrain from use of prohibited medication during the&#xD;
             clinical trial (see section 4.3.5).&#xD;
&#xD;
         16. Subject who is vulnerable (such as deprived of freedom) as defined in Section 1.61 of&#xD;
             the International Conference on Harmonisation (ICH) Guideline for Good Clinical&#xD;
             Practice (GCP).&#xD;
&#xD;
         17. Subject with clinically significant abnormal laboratory finding (if any available&#xD;
             report) at the baseline visit or medical/surgical condition (other than for actinic&#xD;
             keratoses), which might, in the Investigator's opinion, interfere with study&#xD;
             evaluations or pose a risk to subject safety during the study.&#xD;
&#xD;
         18. The subject is a study site staff member (investigator, study nurse, etc.) or a&#xD;
             relative of one.&#xD;
&#xD;
         19. Subjects with any condition that may be associated with a risk of poor protocol&#xD;
             compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajeev CHAVDA, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma R&amp;D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 25, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <results_first_submitted>September 10, 2018</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>field-treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03511326/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Luxerm®</title>
          <description>Methyl Aminolaevulinate 16% Cream: Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Luxerm®</title>
          <description>Methyl Aminolaevulinate 16% Cream: Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.4" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin phototype</title>
          <description>Fitzpatrick skin phototype is a system used to describe a person's skin type. It ranges from skin phototype I to III. Where, skin phototype I = pale white skin, always burns easily, never tans; skin phototype II = fair skin, always burns easily, tans minimally and with difficulty; skin phototype III = darker white skin, burns minimally, tans gradually and uniformly.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Phototype I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phototype II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phototype III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Actinic Keratosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.77" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Subject Satisfaction the Day of Treatment After Daylight Session</title>
        <description>Percentage of subjects satisfied and very satisfied globally with Luxerm Daylight procedure, the day of treatment after daylight session</description>
        <time_frame>the day of treatment after daylight session</time_frame>
        <population>Intent to Treat (ITT) population included all enrolled participants (i.e. treatment dispensed).</population>
        <group_list>
          <group group_id="O1">
            <title>Luxerm®</title>
            <description>Methyl Aminolaevulinate 16% Cream: Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Subject Satisfaction the Day of Treatment After Daylight Session</title>
          <description>Percentage of subjects satisfied and very satisfied globally with Luxerm Daylight procedure, the day of treatment after daylight session</description>
          <population>Intent to Treat (ITT) population included all enrolled participants (i.e. treatment dispensed).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Subject Satisfaction at Week 12 Post-treatment</title>
        <description>Percentage of subjects satisfied or very satisfied (overall) with Luxerm DL procedure</description>
        <time_frame>Week 12</time_frame>
        <population>ITT population included all enrolled participants (i.e. treatment dispensed). Here, the &quot;N&quot; number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Luxerm®</title>
            <description>Methyl Aminolaevulinate 16% Cream: Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Subject Satisfaction at Week 12 Post-treatment</title>
          <description>Percentage of subjects satisfied or very satisfied (overall) with Luxerm DL procedure</description>
          <population>ITT population included all enrolled participants (i.e. treatment dispensed). Here, the &quot;N&quot; number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of Informed Consent Form (ICF) to end of study (Week 12)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Luxerm®</title>
          <description>Methyl Aminolaevulinate 16% Cream: Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin warm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CTA Coordinator</name_or_title>
      <organization>Galderma R&amp;D SNC</organization>
      <phone>+33 0493 95 70 85</phone>
      <email>cta.coordinator@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

